Status:
UNKNOWN
MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis
Lead Sponsor:
National Research Center for Hematology, Russia
Conditions:
Leukemia
Multiple Myeloma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
Evaluating the effectiveness of the new protocol which replace the standard immunosuppressive therapy with use of MSCs and CY in patients at high risk of relapse.
Detailed Description
This trial try to find a new way of refractory hematological malignancies treatment. Aim of this study evaluating the effectiveness of the new protocol which replace the standard immunosuppressive the...
Eligibility Criteria
Inclusion
- Refractory forms of acute leukemia, but in complete remission (CR)
- Second and third remission of acute leukemia
- 2nd and 3rd chronic phase chronic myelogenous leukemia (CML) (or Ph + ALL)
- relapsed multiple myeloma
- advanced leukemia
Exclusion
- ICU
- Mechanical ventilation
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2016
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT02270307
Start Date
January 1 2014
End Date
January 1 2016
Last Update
October 21 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BMT department
Moscow, Russia